drugset / Trial / NCT04789057
Atorvastatin Effect on Reduction of COPD Exacerbations
Phase 4
Active not recruiting
460 enrolled
Medical University of Bialystok
Medical Research Agency, Poland · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
It is a randomized, multicenter, prospective, double-blind, placebo controlled, interventional clinical trial that will be conducted in Poland, in about 12 Hospital Pulmonary Departments to evaluate the effectiveness of atorvastatin on the reduction of inflammation process in patients with chronic obstructive pulmonary diseases, and possible biomarkers for personalized treatment of COPD.
Timeline
- Start
- 2022-02-11
- Primary completion
- 2026-12-31
- Completion
- 2027-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atorvastatin | Small molecule | 40 mg | Oral |